Vitura Health has added nicotine vaping products (NVPs) to its CanView distribution platform as it continues to expand its medicine portfolio beyond cannabis.
The addition of NVPs follows a government crackdown on the use of disposable and non-prescription vapes in its battle to halt child nicotine addiction.
From January 1, the importation of single-use, non-prescription vapes is banned by the Department of Health, while all doctors and nurse practitioners can now prescribe NVPs as a smoking cessation treatment without prior approval from the Therapeutic Goods Administration (TGA).
The regulatory changes are expected to see an upturn in the number of NVP prescriptions issued by GPs.
Vitura said it has signed exclusive agreements with a number of suppliers which currently provide prescription-only NVPs to the Australian market.
Chief executive Rodney Cocks described the new product vertical as “another milestone” for the company.
“We applaud the TGA for the changes that have been implemented with respect to all vaping products and we look forward to supporting patients in their journey to quit smoking and reduce their dependency on nicotine,” he said.
